2578. Trends in Pathogens and Antibiotic Treatment in Children with Cystic Fibrosis in 2018 and 2022: A Retrospective Multicenter Study

BACKGROUND: The new Cystic Fibrosis (CF) transmembrane conductance regulator modulator therapy combination (elexacaftor/tezacaftor/ivacaftor, ETI) has significantly improved the quality of life of children with CF and decreased the rate of pulmonary exacerbations (PEx). The focus of our study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Stout, Dayna, Fireizen, Yaron, Vigers, Timothy, Ahmed, Mohamoud, Akong, Kathryn, Ryu, Julie, Hahn, Andrea, Koumbourlis, Anastassios, Tirakitsoontorn, Pornchai, Arrieta, Antonio C, Burgener, Elizabeth, Towler, Elinor, Keck, Allison, Sagel, Scott, Bradley, John S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678431/
http://dx.doi.org/10.1093/ofid/ofad500.2194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678431/
http://dx.doi.org/10.1093/ofid/ofad500.2194

Ejemplares similares